Fig. 3.

Inter-class analysis results for the combined data from the four clinical studies for those patients who received cetuximab, either as a monotherapy or in combination with the FOLFIRI (folinic acid + 5-fluorouracil + irinotecan) or FOLFOX (folinic acid + 5-fluorouracil + oxaliplatin) regimens. Results at zero-time shift (a) and when maximum cross-correlation coefficients (CC) values are achieved (b) are shown. Horizontal lines show the centroids for each cluster. Table in c details the results of this inter-class analysis for patients who were administered cetuximab. If the cluster centroid value was above 0.35, CCs from that cluster were considered to show similar dynamics and summed to CCs from cluster 3. Note that patient percentages accounted for more than 100%, because a single patient can have lesion pairs in different clusters. d The distribution of time shifts or lags at which the maximum CCs were obtained, within each cluster